A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT06630247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT06630247
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Exelixis
- Industry
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Interventions
- ADC cytotoxic agents Drug
- XL495 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2024
- Primary completion
- May 6, 2025
- Completion
- May 6, 2025
- Last update posted
- Jun 24, 2025
2024 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #4 | Denver | Colorado | 80218 | — |
| Exelixis Clinical Site #9 | New Haven | Connecticut | 06511 | — |
| Exelixis Clinical Site #8 | Washington D.C. | District of Columbia | 20007 | — |
| Exelixis Clinical Site #10 | Jefferson | Louisiana | 70121 | — |
| Exelixis Clinical Site #7 | New York | New York | 10029 | — |
| Exelixis Clinical SIte #2 | Huntersville | North Carolina | 28078 | — |
| Exelixis Clinical Site #3 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #5 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #1 | Austin | Texas | 78758 | — |
| Exelixis Clinical Site #6 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06630247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06630247 live on ClinicalTrials.gov.